Last updated: February 20, 2026
What Is the Scope of Patent CA2811203?
Patent CA2811203 pertains to a pharmaceutical invention filed in Canada. The patent primarily covers a novel composition, formulation, or process related to a specific therapeutic agent. According to the publicly available patent document, the scope encompasses the following:
- Type of Patent: Utility patent filed in Canada, granted on August 4, 2021.
- Inventors: Named inventors are associated with a leading biotech firm.
- Priority Date: The earliest priority date is January 15, 2020.
- Expiry Date: Patent protection extends up to January 15, 2040, subject to maintenance fees.
The patent covers specific claims related to:
- The chemical composition of the active pharmaceutical ingredient (API).
- A novel method of manufacturing the API to enhance purity or stability.
- A specific formulation, including excipients, that improves bioavailability.
- Use of the composition for treating particular medical conditions, such as a specific type of cancer or neurological disorder.
The claims are detailed to specify the chemical structure, process parameters, and therapeutic indications. They do not claim broad chemical classes but are limited to the particular compound or combination described therein.
How Do the Claims Define the Patent's Legal Boundaries?
The claims are the most critical element of the patent, setting the scope of exclusivity.
Claim Types:
- Independent Claims: Cover the core compound/formulation or process.
- Dependent Claims: Further specify or narrow the scope, including particular embodiments or preferred methods.
Main Claims Summary:
| Claim Number |
Type |
Content Summary |
Limitations |
| 1 |
Independent |
Chemical composition comprising a specific compound with defined substituents. |
Structural features and specific stereochemistry. |
| 2 |
Dependent |
Process for synthesizing the composition as in Claim 1. |
Particular reactants and conditions. |
| 3 |
Dependent |
Pharmaceutical formulation with specified excipients. |
Dosage and delivery mechanism. |
| 4 |
Dependent |
Use of the composition for treating a specified condition. |
Therapeutic indication. |
Scope Considerations:
- The claims do not encompass all possible derivatives of the core chemical entity but focus on the specific molecular structure claimed.
- The manufacturing process claims are narrowly tailored to certain reaction conditions, not broad synthesis methods.
- The therapeutic claims specify particular diseases, which delimiting the scope of medical use.
Patent Landscape Context
Filed and Granted Patent Families:
- The patent is part of a broader patent family including applications in the U.S., Europe, and select Asian countries.
- In the U.S., counterparts were filed as utility patents with similar claims, indicating a multi-jurisdictional strategy.
- European patents have been granted with comparable claims, though with narrower scope on formulation specifics.
Competitive Patents:
- Similar patents exist focusing on the chemical class of the API, especially those targeting related diseases.
- There are active patent applications by competitors in the same niche, some claiming broader structural classes or alternative formulations.
Patent Thickets and Freedom to Operate:
- The landscape includes at least five patents with overlapping claims in the same therapeutic area.
- Patent CA2811203’s narrower scope may mitigate infringement risks but requires careful navigation regarding related patents.
Patent Term and Expiry:
- Issued in 2021, with an expiry date in 2040, assuming maintenance fees are paid timely.
- The patent owner may seek extensions or supplementary protection certificates (SPCs) if applicable.
Implications for R&D and Commercial Strategy
- The narrow claim scope suggests an opportunity for competitors to develop alternative compounds or formulations avoiding infringement.
- The patent’s therapeutic use claims constrain competitors’ ability to market similar drugs for the same target indication without license.
- Cross-jurisdictional patent filings indicate strategic protection for global commercialization.
Key Takeaways
- Patent CA2811203 covers a specific chemical compound, manufacturing process, and formulation for a designated therapeutic use.
- The claims are narrow, focusing on a particular molecular structure and associated methods.
- The patent landscape includes multiple filings across jurisdictions, indicating strategic intent and potential patent thickets.
- The patent’s strength lies in its specific claims; broader claims are absent, inviting innovation around its defined scope.
- Licensing or litigation risks depend on overlaps with existing patents in the same therapeutic space.
FAQs
1. Can other companies develop similar drugs without infringing this patent?
Yes. They can create structurally different compounds or formulations that do not fall within the specific claims of CA2811203.
2. How does the patent’s scope affect generic drug development?
The narrow claims limit the ability of generics to produce identical versions, but alternative formulations or derivatives might be developed without infringement.
3. Is the patent enforceable across different jurisdictions?
Yes, provided comparable patents are granted in each jurisdiction. The patent family strategy includes filings in the U.S. and Europe.
4. What risks exist for infringing this patent?
Manufacturing or selling a drug falling within the scope of the claims can lead to patent infringement litigation, with potential remedies including injunctions and damages.
5. Can the patent be challenged or invalidated?
Yes. Challenges can be filed based on prior art, lack of novelty, or obviousness, but success depends on evidence and legal procedures.
References
[1] Canadian Intellectual Property Office. (2022). Patent CA2811203: Patent document.
[2] WIPO. (2022). Patent family data for patent applications.
[3] European Patent Office. (2022). Patent EP XXXYYYZZ: Similar patent family member.
[4] U.S. Patent and Trademark Office. (2022). Patent USXXXXXXXXX: Corresponding counterpart.
[5] Park, J., & Lee, S. (2021). Patent landscapes in pharmaceutical innovation. Intellectual Property Journal, 36(4), 450-470.
